Biotech’s 2026 IPO Class Raised $6.9bn on Late-Stage Assets and Would Be $473m Under Water Without Veradermics
Late-stage assets bought the biggest IPOs of 2026. So far they have cost investors most, and one stock carries the class.
NeuroPulse
DealPulse Signal
The Beats
Analysis
The Briefs
New US Drugs Launched at a Median $257,000 a Year in 2025, and Only About a Third of Their Prescriptions Were Filled Within 30 Days
The UK Wants 92% of Dementia Referrals Diagnosed Within 18 Weeks by 2029, Up From About 60%, and Is Testing Nine Technologies to Get There
Merck KGaA Will Pay $1.3 Billion for Silence Therapeutics, Buying Its Way Into Haematology With One Phase 3-Ready siRNA
Lilly Signed Up to $1.1 Billion With METiS TechBio for AI-Designed Lipid Nanoparticles While Paying Only Low Double-Digit Millions Upfront
The First US Tinnitus Guideline Update Since 2014 Names Bimodal Neuromodulation, Handing Neuromod’s Lenire a Coverage Argument
